¹⁸F-alfatide PET/CT may predict short-term outcome of concurrent chemoradiotherapy in patients with advanced non-small cell lung cancer.

Abstract

The study aims to investigate the role of ¹⁸F-alfatide positron emission tomography/computed tomography (PET/CT) in predicting the short-term outcome of concurrent chemoradiotherapy (CCRT) in patients with advanced non-small cell lung cancer (NSCLC). Eighteen patients with advanced NSCLC had undergone ¹⁸F-alfatide PET/CT scans before CCRT and PET/CT parameters including maximum and mean standard uptake values (SUV_max/SUV_mean), peak standard uptake values (SUV_peak) and tumor volume (TV_PET and TV_CT) were obtained. The SUV_max of tumor and normal tissues (lung, blood pool and muscle) were measured, and their ratios were denoted as T/NT (T/NT_lung, T/NT_blood and T/NT_muscle). Statistical methods included the Two-example t test, Wilcoxon rank-sum test, Receiver-operating characteristic (ROC) curve analysis and logistic regression analyses. We found that SUV_max, SUV_peak, T/NT_lung, T/NT_blood and T/NT_muscle were higher in non-responders than in responders (P = 0.0024, P = 0.016, P < 0.001, P = 0.003, P = 0.004). According to ROC curve analysis, the thresholds of SUV_max, SUV_peak, T/NT_lung, T/NT_blood and T/NT_muscle were 5.65, 4.46, 7.11, 5.41, and 11.75, respectively. The five parameters had high sensitivity, specificity and accuracy in distinguishing non-responders and responders. Multivariate logistic regression analyses showed that T/NT_lung was an independent predictor of the short-term outcome of CCRT in patients with advanced NSCLC (P = 0.032). ¹⁸F-alfatide PET/CT may be useful in predicting the short-term outcome of CCRT in patients with advanced NSCLC.